Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:IMPL Impel Pharmaceuticals (IMPL) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock Analysis About Impel Pharmaceuticals Stock (NASDAQ:IMPL) 30 days 90 days 365 days Advanced Chart Ad Brownstone ResearchMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.I call it my AI Retirement Playbook. I recommend you check it out now. Get Impel Pharmaceuticals alerts:Sign Up Key Stats Today's Range N/A50-Day Range$0.04▼$0.8452-Week Range N/AVolume720,000 shsAverage Volume682,655 shsMarket Capitalization$956,000.00P/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewImpel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. The company was incorporated in 2008 and is headquartered in Seattle, Washington.Read More… Receive IMPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Impel Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IMPL Stock News HeadlinesImpel-Stelda Enters Primary Packaging Business of Tube FillingOctober 12, 2024 | msn.comImexpharm achieves net revenue of US$39.74 million in 2024H1July 26, 2024 | msn.comMost People Are Dead Wrong.Turn on any financial news outlet at any given moment and within minutes you're guaranteed to see headlines about artificial intelligence. Everyone's talking about AI right now. But see, I've been talking about it for years.December 25, 2024 | Brownstone Research (Ad)Compliant Marketing In The Pharmaceutical Industry's Regulatory MazeMay 17, 2024 | forbes.comImpel Pharmaceuticals Inc. (IMPLQ)March 13, 2024 | finance.yahoo.comImpel Pharma Mulls Sale, Signs Stalking Horse Deal; Files For Chapter 11 ProtectionDecember 20, 2023 | markets.businessinsider.comImpel Pharmaceuticals Announces Filing of Voluntary Chapter 11 Cases and Signing of "Stalking Horse" Agreement to Facilitate SaleDecember 20, 2023 | finance.yahoo.comAdrian Adams steps down as CEO of Seattle's Impel PharmaceuticalsNovember 6, 2023 | bizjournals.comSee More Headlines IMPL Stock Analysis - Frequently Asked Questions How were Impel Pharmaceuticals' earnings last quarter? Impel Pharmaceuticals Inc. (NASDAQ:IMPL) issued its quarterly earnings results on Monday, November, 15th. The company reported ($1.24) EPS for the quarter, missing the consensus estimate of ($0.82) by $0.42. The company had revenue of $0.09 million for the quarter. When did Impel Pharmaceuticals IPO? Impel Pharmaceuticals (IMPL) raised $80 million in an initial public offering (IPO) on Friday, April 23rd 2021. The company issued 5,300,000 shares at $14.00-$16.00 per share. Cowen, Guggenheim Securities and Wedbush PacGrow served as the underwriters for the IPO. What other stocks do shareholders of Impel Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Impel Pharmaceuticals investors own include Athenex (ATNX), NIO (NIO), KLX Energy Services (KLXE), American Airlines Group (AAL), Bolt Biotherapeutics (BOLT), Moderna (MRNA) and Novavax (NVAX). Company Calendar Last Earnings11/15/2021Today12/25/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:IMPL CUSIPN/A CIK1445499 Webwww.Impelnp.com Phone206-568-1466FaxN/AEmployees160Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($3.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-106,310,000.00 Net Margins-353.93% Pretax Margin-353.93% Return on EquityN/A Return on Assets-127.43% Debt Debt-to-Equity RatioN/A Current Ratio0.19 Quick Ratio0.13 Sales & Book Value Annual Sales$20.99 million Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.86) per share Price / BookN/AMiscellaneous Outstanding Shares23,900,000Free Float22,418,000Market Cap$956,000.00 OptionableNot Optionable Beta1.17 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:IMPL) was last updated on 12/25/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Impel Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Impel Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.